
To stay sharper while aging, get active, challenge your brain, and eat healthy
That's according to initial results released Monday from a rigorous U.S. study of lifestyle changes in seniors at risk of developing dementia . People following a combination of healthier habits slowed typical age-related cognitive decline — achieving scores on brain tests as if they were a year or two younger, researchers reported in JAMA and at the Alzheimer's Association International Conference.
It's not too late to get started -- study participants were in their 60s and 70s -- and it doesn't require becoming a pickleball champ or swearing off ice cream.
'It was the first time I felt like I was doing something proactive to protect my brain,' said Phyllis Jones, 66, of Aurora, Illinois, who joined the study after caring for her mother with dementia and struggling with her own health problems.
It's too soon to know if stalling age-related decline also could reduce the risk of later Alzheimer's or other forms of dementia. But Jones and other study participants underwent brain scans and blood tests that researchers now are analyzing for clues – such as whether people also saw a reduction in Alzheimer's-related protein buildup.
'We're all on a cognitive aging clock and anything we can do to slow that clock down, to me, that is a significant benefit,' said Laura Baker of Wake Forest University School of Medicine, who led the study.
Doctors have long encouraged physical activity and a healthy diet for brain fitness. Those steps fight high blood pressure and cholesterol, heart disease and diabetes, factors that increase the risk of dementia.
But until now the strongest evidence that specific lifestyle changes later in life could improve how people perform on brain tests came from a study in Finland.
Would it work for a more sedentary and culturally diverse U.S. population? With funding from the Alzheimer's Association and the National Institute on Aging, Baker's team tested the strategy for two years in 2,100 adults ages 60 to 79.
Half of participants were randomly assigned to group classes for exercise and dietary changes plus brain-challenging homework – with peer support and coaches tracking their progress.
They did a half-hour of moderately intense exercise four times a week -- plus twice a week, they added 10 to 15 minutes of stretching and 15 to 20 minutes of resistance training.
They followed the 'MIND diet' that stresses lots of leafy greens and berries plus whole grains, poultry and fish. Nothing is banned but it urges limiting red meat, fried or 'fast food' and sweets, and substituting olive oil for butter and margarine.
They also had to meet someone or try something new weekly and do brain 'exercises' using an online program called Brain HQ.
Other study participants, the control group, received brain-healthy advice and minimal coaching — they chose what steps to follow.
Both improved but the groups fared significantly better.
Combining social engagement with exercise and dietary steps may be key, said Jessica Langbaum of the Banner Alzheimer's Institute, who wasn't involved with the study.
'Americans want to have that one easy thing – 'If I just eat my blueberries,'' Langbaum said. 'There is no one magic bullet. It is a whole lifestyle.'
Moderately intense physical activity means raising your heart rate and panting a bit yet still able to talk, said Wake Forest's Baker. Pick something safe for your physical capability and start slowly, just 10 minutes at a time until you can handle more, she cautioned.
Make it something you enjoy so you stick with it.
Likewise there are many options for brain exercise, Baker said – puzzles, joining a book club, learning an instrument or a new language.
Jones, a software engineer-turned-tester, learned she loves blueberry-spinach smoothies. Her favorite exercise uses an at-home virtual reality program that lets her work up a sweat while appearing to be in another country and communicating with other online users.
Researchers will track study participants' health for four more years and the Alzheimer's Association is preparing to translate the findings into local community programs.
Will people with stick with their new habits?
Jones lost 30 pounds, saw her heart health improve and feels sharper especially when multitasking. But she hadn't realized her diet slipped when study coaching ended until a checkup spotted rising blood sugar. Now she and an 81-year-old friend from the study are helping keep each other on track.
The lifestyle change 'did not just affect me physically, it also affected me mentally and emotionally. It brought me to a much better place,' Jones said.
—-
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
10 minutes ago
- Forbes
Sell HIMS Stock Ahead of Its Earnings?
Hims & Hers Health (NYSE:HIMS) is set to announce its earnings on Monday, August 4, 2025. Historically, HIMS stock has reacted unfavorably to earnings announcements. Since 2021, the stock has recorded a negative one-day return in 53% of instances after results. The median one-day decline has amounted to -5.8%, with a maximum one-day decrease of -22.3%. For traders focused on events, grasping these historical trends can be beneficial. While the actual results compared to consensus and expectations will be vital, there are two main strategies to contemplate: Analysts expect HIMS to report earnings of $0.23 per share on revenues of $552 million. This would mark substantial growth compared to the same quarter last year, which recorded earnings of $0.16 per share on revenues of $315 million. A possible positive factor for Hims & Hers' sales growth momentum is the reported underperformance of Novo Nordisk's weight loss medication in the U.S. due to the presence of compounded versions. Regarding fundamentals, HIMS has a market capitalization of $15 billion. Over the past twelve months, the company generated $1.8 billion in revenue and was operationally profitable, reporting $110 million in operating profits and a net income of $164 million. However, if you're looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and achieved returns exceeding 91% since its inception. Additionally, see – Is There More Upside For MSFT Stock? Review earnings reaction history of all stocks HIMS Stock Historical Likelihood of Positive Post-Earnings Return Here are some insights on one-day (1D) post-earnings returns: Additional information regarding the observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized along with the statistics in the table below. HIMS Stock Correlation Between 1D, 5D, and 21D Historical Returns A comparatively lower-risk strategy (though not effective if the correlation is weak) is to understand the relationship between short-term and medium-term returns post earnings, identify a pair that has the highest correlation, and perform the corresponding trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can take a "long" position for the next 5 days if the 1D post-earnings return is positive. Here is some correlation information based on a 5-year and 3-year (more recent) timeframe. Note that the correlation 1D_5D denotes the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about the Trefis RV strategy that has outperformed its all-cap stocks benchmark (a blend of the S&P 500, S&P mid-cap, and Russell 2000), delivering strong results for investors. Additionally, if you seek upside with a smoother experience than an individual stock like Hims & Hers Health, consider the High Quality portfolio, which has surpassed the S&P and yielded >91% returns since its inception.
Yahoo
31 minutes ago
- Yahoo
SpaceX fires up Starship spacecraft ahead of 10th test flight (video, photos)
When you buy through links on our articles, Future and its syndication partners may earn a commission. SpaceX just fired up its newest Starship spacecraft on Thursday (July 31), to help prep the vehicle for an upcoming test flight. The company conducted a "static fire" trial with the 171-foot-tall (52 meters) Starship upper stage at its Starbase site in South Texas on Thursday, briefly igniting one of the vehicle's six Raptor engines. "Starship single-engine static fire demonstrating an in-space burn complete on Pad 1 at Starbase," SpaceX wrote in a Thursday evening X post that shared two photos and a video of the milestone. The test is part of the prep work for Flight 10 of Starship, the huge, fully reusable rocket that SpaceX is developing to help humanity colonize Mars and do a wide variety of other spaceflight work. Starship consists of two elements — the upper-stage spacecraft, called Starship or simply Ship, and a huge booster known as Super Heavy. Both are made of stainless steel and are powered by Raptors (33 of them in Super Heavy's case). This particular Ship is the second that SpaceX has earmarked for Flight 10. The first exploded on a test stand at Starbase on June 18 just before a planned static-fire test. The Super Heavy that will fly on Flight 10 has already passed its static-fire test, igniting all 33 of its engines on June 6. Related Stories: — SpaceX's Starship explodes in Texas during preparations for 10th test flight — SpaceX reached space with Starship Flight 9 launch, then lost control of its giant spaceship (video) — Starship and Super Heavy explained SpaceX has not yet announced a target date for Flight 10, but we may not have to wait long for it: company founder and CEO Elon Musk has said the test mission will launch in August. A fully stacked Starship first flew in April 2023. The huge rocket has launched three times so far this year, in January, March and May. On all three flights, SpaceX lost the upper stage before its planned Indian Ocean splashdown.
Yahoo
39 minutes ago
- Yahoo
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results. The webcast will be available at the investor relations section of the Company's website at Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data